

# Roving Seminar on WIPO Services and Initiatives

Wellington, New Zealand 15 March 2017

#### Introduction to WIPO





<u>Speaker</u>: Victor Vázquez López, Head Section for Coordination of Developed Countries



#### **MISSION STATEMENT**

"To lead the development of a balanced and effective international intellectual property (IP) system that enables innovation and creativity for the benefit of all."




#### **Facts about WIPO**

- MEMBER STATES: 189
- **OBSERVERS**: more than **390** (NGOs, IGOs, industry groups, etc.)
- STAFF: more than 1200
- ADMINISTERED TREATIES: 26
- MAIN BODIES: General Assembly, CC, WIPO Conference



http://www.wipo.int/multimedia-video/en/about-wipo/wipo.ogg

# **Major Economic Studies on IP**







#### The Global Innovation Index

#### **RANKING 2015**

- 1. SWITZERLAND
- 2. UNITED KINGDOM
- 3. SWEDEN
- 4. NETHERLANDS
- 5. UNITED STATES OF AMERICA
- 6. FINLAND
- 7. SINGAPORE
- 8. IRELAND
- 9. LUXEMBOURG
- 10. DENAMRK
- 11. HONG KONG (CHINA)
- 12. GERMANY
- 13. ICELAND
- 14. REPUBLIC OF KOREA
- 15. NEW ZEALAND

#### **RANKING 2016**

- 1. SWITZERLAND
- 2. SWEDEN
- 3. UNITED KINGDOM
- 4. UNITED STATES OF AMERICA
- 5. FINI AND
- 6. SINGAPORE
- 7. IRELAND
- 8. DENMARK
- 9. NETHERLANDS
- 10. GERMANY
- 11. REPUBLIC OF KOREA
- 12. LUXEMBOURG
- 13. ICELAND
- 14. HONG KONG (CHINA)
- **17. NEW ZEALAND**

WORLD INTELLECTUAL PROPERTY ORGANIZATION

WIPO


#### The Global Innovation Index

Strengths	Weaknesses
Institutions	Graduates in science & engineering, %
Political Environment	GDP/unit of energy use, 2005 PPP\$/kg oil eq
Political Stability & safety	Market capitalization, % GDP
Government effectiveness	Total value of stocks traded, % GDP
Regulatory environment	GERD financed by abroad, %
Rule of law	FDI net inflows, % GDP
Cost of redundancy dismissal, salary weeks	Growth rate of PPP\$ GDP/worker, %
Ease of starting a business	High- & medium-high-tech manufactures, %
Credit	Knowledge diffusion
Ease of getting credit	ICT services exports, % total trade
Ease of protecting minority investors	FDI net outflows, % GDP
Scientific & technical articles/bn PPP\$ GDP	
New businesses/th pop. 15-64.	



# International Applications via WIPO Administered Treaties (1998 to 2015)

PCT, Madrid and Hague Applications




Source: WIPO statistics database; last updated: 11/2016



# Statistics at a glance

- PCT System applications grew nearly 3.5% between 2010 and 2015
- Madrid System applications grew just over 3000% in the same time period



GERD= Gross Expenditure on Research and Development, Source: data.uis.unesco.org/



#### Follow us

Twitter: @wipo

 WIPO Magazine www.wipo.int/wipo\_magazine/en/

 WIPO Wire: www.wipo.int/newsletters/en

Press releases
 www.wipo.int/pressroom/en/





# WIPO Services & Initiatives The Patent Cooperation Treaty (PCT)





Anjali Aeri, Program Officer, PCT International
 Cooperation Division, Patents & Technology Sector

Wellington, New Zealand 15 March 2017



## **Putting Innovation into Practice**

- The PCT is a global solution for innovators
  - One international patent application
  - One form
  - One language
  - One office
  - One set of fees
- Has the effect of a regular national filing in each Member State



#### General remarks on the PCT system


- Only inventions may be protected via the PCT
- The PCT is a <u>patent "filing" system</u>, not a patent "granting" one.
- The decision on granting patents is taken exclusively by national/regional Offices





WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION


## Traditional patent system: "Paris Route"




- Local patent application followed within 12 months by multiple foreign applications claiming priority under Paris Convention:
  - <u>multiple</u> formality requirements
  - <u>multiple</u> searches
  - <u>multiple</u> publications
  - multiple examinations and prosecutions of applications
  - translations and national fees required at 12 months
- Some rationalization because of regional arrangements: ARIPO, EAPO, EPO, OAPI




# **PCT - Seek Patents Globally**
















# International Searching Authorities (22 in total)

- AT Austria
- KR Republic of Korea
- AU Australia
- RU Russian Federation

BR – Brazil

- SE Sweden
- CA Canada
- SG Singapore

CL - Chile

UA – Ukraine

■ CN – China

US – United States of America

■ EG – Egypt

EP – European Patent Office

ES - Spain

- XN Nordic Patent Institute (Denmark, Iceland, Norway)
- FI Finland
- XV Visegrad Patent Institute (VPI)
   (Czech Republic, Hungary, Poland, Slovakia)

■ IL – Israel

TR – Turkish Patent and Trademark Office (operational as from 8 March 2017)

- IN India
- JP Japan

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

#### **Example: PCT International Search Report (PCT/ISA/210)**

C. DOCUM	MENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Х	JP 50-14535 B (NCR CORPORATION) 28 May 1975 (28.05.75), column 4, lines 3 to 27	7-9, 11
X Y A	GB 392415 A (JONES) 18 May 1933 (18.05.33) Fig. 1 page 3, lines 5-7 Fig. 5, support 36	1-3 4, 10 11-12
X Y	GB 2174500 A (STC) 5 November 1986 (05.11.86) page 1, lines 5-15, 22-34, 46-80; Fig. 1	1-3 4
A	US 4322752 A (BIXTY) 30 March 1982 (30.03.82) claim 1	1
A	GREEN, J.P. Integrated Circuit and Electronic Compass, IBM Technical Disclosure Bulletin, ober 1975, Vol. 17, No. 6, pages 1344 and 1345	1-5


Symbols indicating which aspect of patentability the document cited is relevant to (for example, novelty, inventive step, etc.)

Documents relevant to whether or not your invention may be patentable

The claim numbers in your application to which the document is relevant

WIPO

INTELLECTUAL PROPERTY
ORGANIZATION







#### PATENTSCOPE

Search International and National Patent Collections


WORLD INTELLECTUAL PROPERTY ORGANIZATION

Search | Browse | Translate | Options | News | Login NEW! | Help

Home >IP Services >PATENTSCOPE > Database Search


Fields
-ields
Front Page =
AND WIPO Publication Number =
AND Application Number =
AND Publication Date =
AND V English Title V =
AND V English Abstract =
AND V Applicant Name =
AND V International Class =
AND V Inventor Name =
AND V Office Code V =
AND V English Description =
AND V English Claims =
AND Inventor Name Is Empty: • N/A C Yes C No
anguage English Stem 🗸
Office
□ PCT □ Ecuador □ Panama □ ARIPO
☐ Argentina ☐ El Salvador ☐ Peru ☐ EPO
☐ Brazil ☐ Guatemala ☐ Republic of Korea ☐ LATIPAT
☐ Chile ☐ Honduras ☐ Singapore ☑ All
☐ Colombia ☐ Israel ☐ South Africa
☐ Costa Rica ☐ Mexico ☐ Spain
☐ Cuba ☐ Morocco ☐ Uruguay
☐ Dominican Rep. ☐ Nicaragua ☐ Viet Nam
0 results Search Reset
) Add another search field   (-) Reset search fields Tooltip Help






#### **PDFs**

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION








INTELLECTUAL PROPERTY

ORGANIZATION



#### **PCT Coverage: 151 States**

#### Recent accessions:



Kuwait Djibouti Cambodia Costa Rica Côte d'Ivoire

Mali

Malta

Mongolia

Morocco

Namibia

Montenegro

Mozambique

Netherlands

Nicaragua

Niger

Nigeria

Norway

Panama

Oman

Peru

New Zealand

Algeria Angola Antiqua and Barbuda Armenia Australia

Austria Azerbaijan Bahrain

Barbados Belarus

Albania

Belgium Belize Benin

Bosnia and Herzegovina

Botswana Brazil

Brunei Darussalam

Bulgaria Burkina Faso Cambodia Cameroon Canada

Central African Republic

Chad Chile China Colombia Comoros Congo

Croatia Cuba Cyprus Czech Republic Democratic People's Republic of Korea

Denmark Djibouti Dominica

Dominican Republic

Ecuador Egypt El Salvador **Equatorial Guinea** 

Estonia Finland France, Gabon Gambia Georgia Germany Ghana Greece Grenada Guatemala

Guinea

Guinea-Bissau Honduras Hungary Iceland India Indonesia Iran (Islamic Republic of) Ireland Israel Italy

Japan Kazakhstan Kenva Kuwait Kyrgyzstan Lao People's Dem Rep.

Latvia Lesotho Liberia

Libyan Arab Jamahiriya Liechtenstein

Lithuania Luxemboura Madagascar Malawi Poland Malaysia Portugal Qatar Mauritania

Republic of Korea Republic of Moldova Mexico Romania Monaco

Rwanda

Russian Federation Saint Lucia

Saint Vincent and the Grenadines San Marino

Sao Tomé e Principe

Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia

Papua New Guinea Slovenia South Africa **Philippines** Spain

Sri Lanka Sudan Swaziland St. Kitts and Nevis Sweden

Switzerland Syrian Arab Republic

**Tajikistan** 

Thailand

The former Yugoslav Republic of Macedonia

Togo

Trinidad and Tobago

Tunisia Turkev Turkmenistan Uganda Ukraine

United Arab Emirates

United Kingdom


United Republic of Tanzania United States of America

Uzbekistan Viet Nam 7ambia Zimbabwe

#### WIPO


WORLD INTELLECTUAL PROPERTY ORGANIZATION

# **PCT Applications**



Forecast: +3.3% in 2016


## Filings by country of origin



- 75% from top 5 countries; 92+% of filings from top 15 countries
- PCT applications filed by applicants from 132 countries
- Very close to having 80% of UN member countries in the PCT



#### PCT use in NZ



- PCT Member since 1992
- 262 PCT applications filed by NZ applicants in 2015 with RO/NZ



#### The PCT... and business

Most businesses worldwide which seek and use patents wish to:

- control costs while preserving options
- make informed business decisions
- use the best tools available when seeking protection

The PCT responds to these objectives



# **PCT Advantages (1)**

The PCT, as the cornerstone of the international patent system, provides a worldwide system for simplified filing and processing of patent applications, which—

1. postpones the major costs associated with internationalizing a patent application



# **PCT Advantages (2)**


The PCT, as the cornerstone of the international patent system, provides a worldwide system for simplified filing and processing of patent applications, which—

- postpones the major costs associated with internationalizing a patent application
- 2. provides a strong basis for patenting decisions



# So, why use the PCT?

### Traditional Patent System vs PCT System



# PCT Advantages (3)

The PCT, as the cornerstone of the international patent system, provides a worldwide system for simplified filing and processing of patent applications, which—

- 1. postpones the major costs associated with internationalizing a patent application
- 2. provides a strong basis for patenting decisions
- 3. harmonizes formal requirements



## Harmonization of formal requirements

PCT Article 27(1): "No national law shall require compliance with requirements relating to the form or contents of the international application different from or additional to those which are provided for in this Treaty and Regulations."

PCT Applicant's Guide, paragraph 4.011: "There is a prescribed form for the international application. This form must be accepted by all designated Offices for the purposes of the national phase, so that there is no need to comply with a great variety of widely differing formal requirements in the many countries in which protection may be sought."



# **PCT Advantages (4)**

The PCT, as the cornerstone of the international patent system, provides a worldwide system for simplified filing and processing of patent applications, which—

- 1. postpones the major costs associated with internationalizing a patent application
- 2. provides a strong basis for patenting decisions
- 3. harmonizes formal requirements
- 4. protects applicant from certain inadvertent errors



### Protection from inadvertent errors

- invited corrections of defects & fee payments
- non-competent receiving Office
- double formality review
- restoration of the right of priority
- missing parts/incorporation by reference
- rectification of obvious mistakes
- excuse of national phase entry delay




# PCT Advantages (5)

The PCT, as the cornerstone of the international patent system, provides a worldwide system for simplified filing and processing of patent applications, which—

- 1. postpones the major costs associated with internationalizing a patent application
- 2. provides a strong basis for patenting decisions
- 3. harmonizes formal requirements
- 4. protects applicant from certain inadvertent errors
- 5. evolves to meet user needs
- 6. is used by the world's major corporations, universities and research institutions when they seek multinational patent protection



### Distribution of PCT Applicants in 2015



- **Businesses**: Huawei Technologies CN 3,898 applications published
- Universities: University of California US 361 applications published
- Government and Research Institutions Commissariat à l'Énergie
- Atomique et aux Énergies Alternatives FR 409 applications published



# **Top PCT Applicants 2015\***

() of published	1. Huawei Technologies—CN (3,898)**	+450
PCT applications	2. Qualcomm—US (2,442)	
	3. ZTE—CN (2,155)	
20% of PCT applicants were responsible for more than 80% of the published applications	4. Samsung—KR (1,683)	+300, up from #11
	5. Mitsubishi Electric—JP (1,593)	
	6. Ericsson—SE (1,481)	
	7. LG Electronics—KR (1,457)	+320, up from #16
	8. Sony—JP (1,381)	+400, up from #21
	9. Philips—NL (1,378)	
	10. Hewlett-Packard—US (1,310)	+485, up from #25
	11. Siemens—DE (1,292)	
*48,539 total PCT applicants in 2015	2. Intel—US (1,250)	2015:
	13. Bosch—DE (1,247)	85% businesses
	14. Boe Technology—CN (1,227)	8% individuals
	15. Toyota—JP (1,214)	
	16. Panasonic—JP (1,185)	5% universities
	17. Hitachi—JP (1,165)	2% government and research institutions
**more than 15 per WIPO working	18. Halliburton—US (1,121)	WIPO
	19. Sharp—JP (1,073)	WORLD INTELLECTUAL PROPERTY ORGANIZATION
day	20. Tencent Technology—CN (981)	

## **Top University PCT Applicants 2015**

- University of California (US)
- 2. MIT (US)
- 3. Johns Hopkins (US)
- 4. University of Texas (US)
- 5. Harvard University (US)
- 6. University of Michigan (US)
- 7. University of Florida (US)
- 8. Tsinghua University (CN)
- 9. University of Tokyo (JP)
- 10. Stanford University (US)
- 11. Seoul National University (KR)
- 12. Peking University (CN)
- 13. Columbia University (US)
- 14. Isis Innovation Limited (GB)
- 15. Cornell University (US)
- 16. University of Pennsylvania (US)
- 17. Kyoto University (JP)
- 18. Korea University (KR)
- 19. CalTech (US)
- 20. Danemarks Tekniske Universitet (DK)



# **Top PCT NZ Applicants 2015**

Applicant	<b>Publication</b>	Rank
FISHER & PAYKEL HEALTHCARE LIMITED	51	431
AUCKLAND UNISERVICES LIMITED	14	1466
LANZATECH NEW ZEALAND LIMITED	12	1688
POWERBYPROXI LIMITED	11	1826
VICTORIA LINK LIMITED	11	1826
CROWN EQUIPMENT LIMITED	7	2702
WARATAH NZ LIMITED	7	2702
COMPAC TECHNOLOGIES LIMITED	5	3595
NINE IP LIMITED	5	3595
SNPSHOT TRUSTEE LIMITED	5	3595

http://www.wipo.int/ipstats/en/statistics/country\_profile/NOFILE PROPERTY profile.jsp?code=NZ

### **PCT Testimonial: Inventor**

Professor Shuji Nakamura—co-winner of the 2014 Nobel Prize for Physics for his work on blue LED technology—is quoted in a December 2014 WIPO Magazine article:



"... The PCT is critical for these early stage technologies because it gives us the opportunity to protect our patents globally while allowing the market and the technology to mature further before determining which countries might be most valuable to commercial partners."



# **PCT Advantages (6)**

The PCT, as the cornerstone of the international patent system, provides a worldwide system for simplified filing and processing of patent applications, which—

- 1. postpones the major costs associated with internationalizing a patent application
- 2. provides a strong basis for patenting decisions
- 3. harmonizes formal requirements
- 4. protects applicant from certain inadvertent errors
- 5. evolves to meet user needs
- 6. is used by the world's major corporations, universities and research institutions when they seek multinational patent protection
- 7. can result (if PCT reports are positive) in accelerated national phase processing (PCT-PPH)


CTUAL PROPERTY

# Patent Prosecution Highway (PPH) and PCT

- Accelerated examination in the national phase based on a positive work product of an International Authority (written opinion of the ISA or the IPEA, IPRP (Chapter I or II))
- Conditions:
  - At least one claim has been determined by the ISA or the IPEA to meet the PCT criteria of novelty, inventive step and industrial applicability; and
  - ALL the claims must sufficiently correspond to the claims deemed to meet the PCT criteria (they are of the same or similar scope or they are of narrower scope than the claims in the PCT application)
- Global PPH and PCT:
  - Introduction of Global PPH Pilot in January 2014
  - Single set of qualifying requirements that simplifies the existing PPH network so that it is more accessible for users wipo

# **Work-Sharing under the PCT**

- Patent Prosecution Highway (PPH)
- 112 PCT-PPH pathways for applicants to obtain fast track examination procedure





#### As of 1st of July 2016





### What's next?

- <u>ePCT</u>
- PATENTSCOPE
- WIPO Pearl
- Licensing Availability
- Third Party Observations
- PCT Training Options


### ePCT – a paperless environment

- WIPO online portal that provides e-Services for both applicants and Offices
- User interface available in all (10) PCT publication languages
- Provides secure and direct electronic access to/interaction with International Bureau's PCT application files by applicants/agents
- 30'000 users (5'000 very active in Private Services) in over 100 countries (e.g. US, CA, AU, TR, IN, SE, FI and BR), 67 offices
- ePCT-Filing: -based electronic filing of new PCT applications42 ROs accepting ePCT Filings
- More information: <a href="https://pct.wipo.int/ePCT">https://pct.wipo.int/ePCT</a>




# ePCT – Big Picture






Published IAs for National Phase entry



WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

### **PATENTSCOPE**





WORLD INTELLECTUAL PROPERTY ORGANIZATION

# National/regional collections vs national phase

### Offices for which PCT national phase information is available in PATENTSCOPE Search Service


Where information is displayed for an office, this indicates that the applicant has requested national phase processing for the application concerned in that office. The national entry date and national reference number are supplied by the national office concerned and can be used to retrieve further details from that office, if desired. The information is updated at different frequencies, depending on the office. Therefore, absence of information for a given office does not necessarily indicate a non-entry in that office. The information displayed on the National Phase Tab is based on data supplied to WIPO by the following national patent offices:

Updated: September 19, 2015

https://patentscop	e.wipo.int	:/search/e	n/natio	onalphase.jsf
African Regional Intellectual Property Organization	April 30, 1998	August 6, 2008	1,076	
Austria	November 28, 1980	November 30, 2011	3,178	
Australia	December 5, 1997	October 30, 2015	287,698	
Bulgaria	January 6, 2004	December 19, 2007	241	
Belarus	February 7, 2007	June 15, 2007	31	
Belize	November 13, 2002	February 9, 2007	103	
Canada	January 23, 1992	May 25, 2015	503,006	
Switzerland	July 8, 2008	October 2, 2015	414	
China	July 4, 1995	December 20, 2012	595,797	
Cuba	November 3, 2009	June 24, 2011	287	
Czech Republic	November 9, 1990	November 18, 2014	27,913	
Germany	November 20, 1980	Δnril 29 2011	102 /26	




### **WIPO Pearl**





### **WIPO Pearl**

http://www.wipo.int/wipopearl/search/home.html





### **WIPO Pearl**


- WIPO's online terminology database
- 17'000 concepts, 115'000 terms
- 10 languages
- Contents validated by WIPO language experts and terminologists



### Indication of availability for license

- PCT applicants can indicate in relation to their published applications that the invention is available for license
  - How? Applicants may submit a "licensing request" (see PCT Form <u>PCT/IB/382</u>) directly to the IB
  - When? At the time of filing or within 30 months from the priority date
  - Free of charge
  - Applicants can file multiple licensing requests or update previously submitted ones (within 30 months from the priority date); such requests may be revoked by the applicant at any time, that is, also after 30 months from the priority date
- Submitted licensing indications made publicly available after international publication of the application on PATENTSCOPE under "Bibliographic data" tab with a link to the submitted licensing request itself
- International applications containing such licensing indication requests can be searched in PATENTSCOPE
- Most use thus far from universities/research institutions

### Interface: Field Combination - Structured



Additional search fields can be selected



# **Third Party Observations**

- Allows third parties to submit prior art observations relevant to <u>novelty</u> and <u>inventive step</u> as to published PCT applications
  - Goal: Improve patent quality--give national offices (and PCT Authorities) better/more complete information on which to base their decisions
- Web-based system using in PATENTSCOPE or via ePCT public services

  PCT Biblio. Data Description Claims National Phase Notices Drawings Documents
- Free-of-charge
- Submissions possible until the expiration of <u>28 months</u> from the priority date


Latest bibliographic data on file with the International Bureau

- Applicants may submit comments in response to submitted observations until the expiration of <u>30 months</u> from the priority date
- Anonymous submission of third party observations possible



### **Third Party Observations**

- The Third Party Observation system enables applicants and third parties to submit observations for use by examining Offices
- Accessible through PatentScope



Accessible through ePCT



# **PCT Training Options**

- 29 PCT training videos on <u>WIPO's Youtube channel</u> and WIPO's PCT page
- PCT <u>distance learning course</u> content available in the 10 PCT publication languages
- PCT webinars
  - providing free updates on developments in PCT procedures, and PCT strategies—previous webinars are archived and freely available
  - upon request also for companies or law firms, for example, for focused training on how to use ePCT
- In-person PCT <u>seminars</u> and training sessions
- Advanced PCT Seminar on WIPO premises (each Fall)

### **PCT Resources/Information**

For further information about the PCT, see

http://www.wipo.int/pct/en/

For general questions about the PCT, contact the PCT Information Service at:

Telephone: (+41-22) 338 83 38

Facsimile: (+41-22) 338 83 39

E-mail: pct.infoline@wipo.int





### Thank you!

Anjali Aeri
Program Officer
PCT International Cooperation Division
+ 41 22 338 70 66
anjali.aeri@wipo.int




# Resolving IP Disputes outside the Courts through WIPO ADR



<u>Speaker</u>: Victor Vázquez López, Head, Section for Coordination of Developed Countries

Wellington, New Zealand 15 March 2017

# Top Ten Priorities in Parties' Choice of Dispute Resolution Clause




### **WIPO Arbitration and Mediation Center**

- Helps parties resolve <u>IP and technology disputes outside</u> the courts (alternative dispute resolution: ADR)
  - Mediation
  - Arbitration; Expedited arbitration
  - Expert determination
  - Domain name dispute resolution
- WIPO mediators, arbitrators and experts experienced in IP and technology
  - Delivering informed results efficiently
- WIPO Rules tailored to IP and technology disputes
- Competitive fees
- International neutrality



# WIPO ADR – Areas of Dispute



### **WIPO ADR**

- WIPO case administration prioritizes time and costs
- Domestic and international disputes (25/75%)
- Location of case decided by parties
- 1,500+ mediators and arbitrators, globally, for appointment
- Amounts in dispute from USD 20,000 to USD 1 billion
- Enforceable arbitration awards (New York Convention)
- Confidential



## WIPO Services for Trademark Owners Against Cybersquatting

- 1999: WIPO-created <u>international</u> administrative ADR procedure; Uniform Domain Name Dispute Resolution Policy (UDRP)
- Allows trademark owners to resolve "clear cut" cases of abusive domain name registration and use ("cybersquatting")
- Significantly <u>quicker and cheaper</u> than court litigation
  - Two-month average
  - Fixed fees (USD 1,500)
  - Paperless filing




## WIPO Services for Trademark Owners Against Cybersquatting continued

- 16 years' experience: 36,000 WIPO cases covering 66,000 domain names
  - Parties from 177 countries
  - Multilingual case administration
- Key online resources for parties
  - WIPO <u>Jurisprudential Overview</u> of Selected UDRP Questions
  - WIPO <u>Legal Index</u> of UDRP Decisions



## WIPO Domain Name Cases – Top 10 Areas of Complainant Activity





## **WIPO Mediation Example: IT Dispute**

- 2012 European airline agreement with a US software company re. development of worldwide platform for the management of ticket sales
- 2013 professional services agreement: detailed description of the project as well as the support services to be delivered by the software company
- WIPO mediation followed by WIPO expedited arbitration clause
- Airline paid several million USD for the application
- 2015 airline terminated the agreement
- Software company requested that the software be returned
- Airline initiated mediation
- Result: new license



#### **Further Information on WIPO ADR Services**

- Queries and case filing: arbiter.mail@wipo.int
- WIPO Rules, neutrals and case examples: www.wipo.int/amc/
  - Model clauses:
    <u>www.wipo.int/amc/en/clauses/</u>
- WIPO Domain Name Dispute Resolution: www.wipo.int/amc/en/domains/
- Subscribe: WIPO ADR Highlights Newsletter www.wipo.int/newsletters-archive/en/adr\_highlights.html





## International Registration System of Marks, Madrid –

Management and Maintenance of the International Registration



Matthew Forno
Senior Counsellor, Information and Promotion Division, Madrid Registry

Wellington, New Zealand
15 March 2017

### **Protection Options**

- The national route file trademark application/s with the IP Office of each country in which you want protection
- The regional route apply through a regional trademark registration system with effect in all member states (ARIPO, Benelux Office for IP, EUIPO and OAPI)
- The international route file through the Madrid System

#### **The International Route**

The Madrid System may be preferred when you:

- Seek protection in multiple markets, particularly if these are in different regions
- Want flexibility to add new markets as your export plans develop
- Have limited budget and/or time to spend on registration and management of your trademarks



## The Madrid System is Convenient

- Access a centralized filing and management procedure
- File one application, in one language and pay one set of fees for protection in multiple markets
- Expand protection to new markets as your business strategy evolves



### The Madrid System is Cost-effective


- File an international application, which is the equivalent of a bundle of national applications, effectively saving time and money
- Avoid paying for translations into multiple languages or working through the administrative procedures of multiple IP Offices

## The Madrid System Offers Broad Geographic Coverage

- Currently: 114 countries covered by the 98 members
- Markets that represent more than 80% of world trade
- Recent accessions include:
  - 2013: India, Rwanda and Tunisia
  - 2014: OAPI and Zimbabwe
  - 2015: Algeria, Cambodia, The Gambia and Lao People's Democratic Republic
  - 2016: Brunei Darussalam



### **Members of the Madrid System**



\*All are party to the Protocol, the governing treaty, while 55 are also party to the Agreement

#### **Accession Outlook - 2017/19**

- Africa
  - Malawi
  - Mauritius
  - South Africa

- Asian
  - Indonesia
  - Malaysia
  - Sri Lanka
  - Thailand

- Latin America &
  - the Caribbean
    - Brazil
    - El Salvador
    - Trinidad and Tobago

- Arab Countries
  - Jordan
  - Saudi Arabia

- North America
  - Canada



## **How the Madrid System Works**

#### The International Trademark Registration Process





### Stage 1

#### Application through your Office of origin

- To be entitled to use the Madrid System, you must:
  - Have a real and effective industrial or commercial establishment in, or
  - Be domiciled in, or
  - Be a national of a member of the Madrid System
- Before filing an international application, you need to have registered or filed an application (basic mark) in your Office of origin
- Submit an international application through this same IP Office, which will certify and forward it to WIPO



## Stage 2

#### Formal examination by WIPO

- WIPO conducts a formalities examination
- Once requirements have been met, the mark is recorded in the International Register
- WIPO sends a certificate of international registration to the holder and notifies the IP Offices, of the designated Contracting Parties, in which protection is sought
- The scope of protection is not known at this stage. It is only determined after substantive examination and decision by the IP Offices, as outlined in Stage 3

## Stage 3

Substantive examination by IP Offices (Office of the designated Contracting Party)

- IP Offices make a decision within 12 or 18 months in accordance with their legislation. WIPO records the decisions and notifies you
- If an IP Office refuses to protect your mark, it will not affect the decisions of other offices. You can contest a refusal decision before the IP Office concerned
- If an IP Office accepts to protect your mark, it will issue statement of grant of protection
- The international registration is **valid for 10 years**.

  Renew directly with WIPO with effect in the designated Contracting Parties

LECTUAL PROPERTY

#### Costs

#### Fees are payable to WIPO in Swiss francs

- Basic fee\*, which includes 3 classes of goods/services
  - 653 Swiss francs b/w reproduction of mark
  - 903 Swiss francs color reproduction of mark
- Fees for designating Contracting Parties (dCP)
  - Standard fees complementary (100 Swiss francs per dCP and supplementary (100 Swiss francs per class beyond 3)

OR

Individual fees where this is declared



<sup>\*</sup> Applicants from Least Developed Countries benefit from a 90% reduction in the basic fee


## **Madrid System: Key Figures**

Description	Number
International registrations	44,726
Renewals	29,218
Active international registrations	634,600
Active designations in international registrations	5,714,9 09
Overall Madrid share (non-resident trademark filing, Madrid members only)	63%




## **International Applications**

#### Figure A.1.1 Trend in international applications





### **Top Filing Origins**



Origin




## **Top Applicants**

#	Name	Origin	Applications
1	NOVARTIS	Switzerland	197
2	LIDL STIFTUNG & CO. KG	Germany	142
3	L'ORÉAL, SOCIEITE ANONYME	France	130
4	RICHTER GEDEON NYRT.	Hungary	126
5	PHILIPS ELECTRONICS N.V.	Netherlands	123
6	DAIMLER AG	Germany	99
7	APPLE INC.	USA	86
8	BIOFARMA	France	80
9	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	Germany	69
10	GLAXO GROUP LIMITED	United Kingdom	68



## **Top Designated Contracting Parties**




Madrid member


## International Applications and Registrations: New Zealand

International Applications and Registrations by Office of Origin:

New Zealand




## Designations of New Zealand by Madrid Members



Designations of New Zealand in International Registrations and Subsequent Designations by Country of Holder (2015)



## Top 10 Designated Madrid Members by New Zealand Holders



Designations in International Registrations and Subsequent Designations by designated Contracting Parties, Country of Holder: New Zealand (2015)



#### Online Resources and E-Services

- The Madrid Website provides information on how to search before filing, file an application and how to monitor and manage your registration.
- Madrid E-Services are available to assist you at each stage of your mark's lifecycle:



#### Online Resources and E-Services

search

file

monitor

manage

#### Global Brand Database

- search existing marks from national & international sources
- trademarks, appellations of origin and emblems

# Madrid Goods & Services Manager

 compile a list of approved goods & services terms in 18 languages

#### Member Profiles Database

#### Madrid Monitor

- track real-time status of registration
- watch competitors' marks
- e-alerts
- consult the WIPO Gazette

#### Madrid Portfolio Manager

- access documents
- request changes
- designate, modify & renew
- pay fees
- obtain extracts

WIPO

INTELLECTUAL PROPERTY
ORGANIZATION

### **Developments**

- New IT platform Madrid International Registrations Information System (MIRIS)
- Legal developments: Rules Changes and Madrid System Working Group/Roundtable
- Classification Guidelines
- WIPO Current Account

### **Legal Developments**

Amendments to the Common Regulations

Madrid System Working Group - WG (June 19 to 22, 2017)

- Possible simplification of the replacement procedure
- Analysis of responsibility in examining limitations (roles of the Office of Origin and Office of the dCPs)

Madrid System Roundtable (June 19 to 22, 2017)

- Classification guidelines
- Correspondence of marks Questionnaire



#### **Classification Guidelines**

- Purpose to decrease irregularities
- Describes the classification practices at WIPO
- Divided into three sections -
  - General information Nice Classification and Madrid
  - Classification principles applied by WIPO
  - Practical information on the acceptable format to list indications of goods and services




### **WIPO Current Account Changes**

- No minimum number of transactions
- Initial payment of CHF 2,000
- Minimum balance notification sent to customers if balance is less than CHF 200
- A form to open the account available on the website
- Email address required
- Account statement sent by email only

## Keep Updated on the Madrid System

- Visit the Madrid Website <u>www.wipo.int/madrid/en</u>
- Subscribe to
   Madrid Notices,
   our regular legal
   and news updates
- Sign up forMadrid Highlights





## Thank you for your attention

matthew.forno@wipo.int




# Global IP Infrastructure



Yo TAKAGI, Assistant Director General Global Infrastructure Sector

Wellington, New Zealand 15 March 2017

# **Big Data!**



Source: Gartner



### WIPO's response


- Legal Framework (IP treaties)
- Systems (PCT, Madrid, Hague, AMC)
- Global IP Infrastructure
  - Global IP Data Standardization (IPOs)
  - Global generation of digital IP data (IPOs)
- → Global Databases (IPOs and users)
- Global Platforms (IPOs and users)

# Use Global Databases to increase IP intelligence for Your Business Strategy

- Find a good name for your company and product/service Global Brand Database
- Design your new productGlobal Design Database
- Make sure that your idea/technology is new PATENTSCOPE
- Check if your target markets protect your IP WIPO Lex



# Global IP Databases: Access point



WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION


#### **Global Brand Database**

- Over 28 million records relating to nationally and internationallyprotected trademarks
- Allows searches across multiple collections, including:
  - Trademarks registered under Madrid System and EUIPO
  - Appellations of Origin registered under Lisbon System
  - Emblems protected under the Paris Convention 6ter
  - 31 national collections, with more to come soon





#### **Global Brand Database**



INTELLECTUAL PROPERTY

ORGANIZATION


#### **IMAGE SEARCH**

- Sort your results by their visual similarity to an image you provide
- World's first public trademark database to provide search by image
- Choose the search strategy best suited to your particular mark





# Image Search Use of AI to match similar images



Sort by Relevance - desc ▼



























































































헤





































































## **Global Design Database**



- Launched in 2015
- Simultaneous search of more than 1.7 million industrial designs registered in 6 national collections or under the Hague System

# iWatch in the Global Design Database




WORLD

ORGANIZATION


INTELLECTUAL PROPERTY

# An example of a Design Database Entry






#### **PATENTSCOPE**



WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION




- 3.1 million published PCT applications
- 60 million patent documents (40 regional or national collections)

5 Great TIPS!









Registered

# **TIP 2 Cross Lingual Search**






## **Example: Drone**



#### 50% more results






# **TIP 3 Chemical Compounds Search**

- Recognize chemical compounds in patent texts and from embedded drawings included in patent texts
- Standardize all the different representations of chemical structures into Inchikeys and annotate the document

Implement search functions for Inchikeys that can be used by non chemists





## **Example: Panadol®**

Panadol

Absorbed faster 

than regular Panadol tables
Effective on pain 
Gentle on stomachr. 


TABLETS

Seltvanic conses PRACTIANC. 50mg AUST 8 16045

(1) IUPAC name

N-(4-hydroxyphenyl)acetamide

(2) Skeletal formula



InchiKey
RZVAJINKPMORJF-UHFFFAOYSA-N

(3) International Non proprietary Name (INN)

**Paracetamol** 

(4) Trademark, generic name, other names

Panadol, Tylenol, Acetaminophen, etc.



# Chemical Compounds Search Log In First!







#### **PATENTSCOPE**

Search International and National Patent Collections



# **Chemical Compound Search**




#### Draw or edit:

- Chemical structures
- Reactions
- Fragments similar to chemical sketches on paper




#### **Convert Structure**



- PCT/US chemically indexed since 1978(PCT) and 1979(US)
- Code/clinical/chemical/commercial/CAS/INN names
- Exact compounds can be searched no Markush structures



#### Example: Panadol (Paracetamol)



A61K 8/66

G04N 27/227

PCT/EP2016/067328

□ DCT/ED2016/067460

4. WO/2017/013228 HAND-HELD TEST METER WITH FLUID INGRESS DETECTION CIRCUIT

comprise a DNA repair enzyme and a phycobiliprotein.

GREENALTECH, S.L.

The invention relates to compositions for repairing the adverse effects of the environment daily stress, sun exposure or premature-aging on human skin which

LIEEGCAN GOOTLAND LIMITED



RUIZ CANOVAS, Eugenia

26.01.2017

HAMED Malcolm D

WO



#### PATENTSCOPE

Search International and National Patent Collections

WORLD INTELLECTUAL PROPERTY ORGANIZATION

Translate Browse

User: yo.takagi@wipo.int

Help

Home > IP Services > PATENTSCOPE

Notices

Options

Machine translation

1. (WO2017012647) NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS

Compounds

Latest bibliographic data on file with the International Bureau Submit observation

PermaLink @

Pub. No.:

WO/2017/012647 Publication Date: 26.01.2017

PCT Biblio, Data | Description | Claims | National Ph

International Application No.: PCT/EP2015/066520

International Filing Date: 20.07.2015

IPC:

Search

C07D 471/04 (2006.01), A61K 31/437 (2006.01), A61P 29/00 (2006.01), A61P 37/08 (2006.01), A61P 35/00 (2006.01)

Applicants:

GALAPAGOS NV [BE/BE]; Generaal De Wittelaan L11/A3 B-2800 Mechelen (BE)

Inventors:

MENET, Christel, Jeanne, Marie: (BE).

MAMMOLITI, Oscar: (BE). QUINTON, Evelyne; (BE)

JOANNESSE, Caroline, Martine, Andrée-Marie; (BE).

DE BLIECK, Ann; (BE). BLANC, Javier; (ES)

Agent:

BAR, Grégory, Louis, Joseph: (BE)

Priority Data:

Title

(EN) NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY

DISORDERS

(FR) NOUVEAUX COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT POUR LE TRAITEMENT DE

TROUBLES INFLAMMATOIRES

Abstract:

(EN)The present invention discloses compounds according to Formula (I), wherein R1. R3, R4, R5, L1, and Cv are as defined herein. The present invention also provides

compounds, methods for the production of said compounds of the invention. pharmaceutical compositions comprising the same and their use in allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 and/or interferons. The present invention also methods for the prevention and/or treatment of the

aforementioned diseases by administering a compound of the invention.

(FR)La présente invention concerne des composés de formule (I), dans laquelle R1, R3,

R4, R5, L1, et Cy sont tels que définis dans la description. La présente invention concerne également des composés, des procédés de production desdits composés, des

compositions pharmaceutiques les comprenant et leur utilisation dans des troubles

allergiques ou inflammatoires, des maladies auto-immunes, des maladies prolifératives, des rejets de transplantation, des maladies impliquant un trouble du renouvellement du cartilage, des malformations congénitales du cartilage, et/ou des maladies associées à une hypersécrétion de l'IL-6 et/ou des interférons. La présente invention concerne également des méthodes de prévention et/ou de

traitement de ces maladies consistant à administrer un composé de l'invention.

Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA,

MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG,

SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


African Regional Intellectual Property Organization (BW. GH. GM. KE, LR, LS, MW. MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)

WIPO WORLD INTELLECTUAL PROPERTY ORGANIZATION



#### PATENTSCOPE

Search International and National Patent Collections



WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

to reduce or prevent, respectively, cartilage degradation in the joints of said patient, and preferably terminate, the self-perpetuating processes responsible for said degradation. In a particular embodiment said compound may exhibit cartilage anabolic and/or anti-catabolic properties.

[0208] Injection dose levels range from about 0.1 mg/kg/h to at least 10 mg/kg/h, all for from about 1 to about 120 h and especially 24 to 96 h. A preloading bolus of from about 0.1 mg/kg to about 10 mg/kg or more may also be admi exceed about 2 g/day for a 40 to 80 kg human patient.

[0209] For the prophylaxis and/or treatment of long-term conditions, s months or years so oral dosing is preferred for patient convenience a doses per day are representative regimens. Using these dosing patte with particular doses each providing from about 0.1 to about 10 mg/k

[0210] Transdermal doses are generally selected to provide similar of

[0211] When used to prevent the onset of a condition, a compound of on the advice and under the supervision of a physician, at the dosage include those that have a family history of the condition, or those who developing the condition.

[0212] A compound of the invention can be administered as the sole other compounds that demonstrate

the same or a similar therapeutic activity and that are determined to s administration of two (or more) agents allows for significantly lower d

[0213] In one embodiment, a compound of the invention or a pharma medicament. In a specific embodiment, said pharmaceutical compos

[0214] In one embodiment, a compound of the invention is co-admini involving inflammation; particular agents include, but are not limited t dexamethasone), cyclophosphamide, cyclosporin A, tacrolimus, Myc acetaminophen, ibuprofen, naproxen, and piroxicam.

[0215] In one embodiment, a compound of the invention is co-admini rheumatoid arthritis); particular agents include but are not limited to a Sulfasalazine example but without limitation methotrexate, leflunomide, sulfasalazi azathioprine, and ciclosporin), and biological DMARDS (for example

myeloproliferative disease and leukaemia.

**s**=0

the regimen for treatment usually stretches over many one to five and especially two to four and typically three oral bout 0.01 to about 20 mg/kg of a compound of the invention. ut 5 mg/kg.

eady state levels. The maximum total dose is not expected to

hieved using injection doses.

ed to a patient at risk for developing the condition, typically its at risk for developing a particular condition generally testing or screening to be particularly susceptible to

stered in combination with other therapeutic agents, including

bined administration. In a specific embodiment, coreducing the side effects seen.

a compound of the invention is administered as a ther active ingredient.

agent for the treatment and/or prophylaxis of a disease . azathioprine, corticosteroids (e.g. prednisolone or -CD3 (OKT3, e.g. Orthocolone®), ATG, aspirin,

agent for the treatment and/or prophylaxis of arthritis (e.g. lammatory drugs (NSAIDS), steroids, synthetic DMARDS (for lalate, penicillamine, chloroguine, hydroxychloroguine, Etanercept, Adalimumab, Rituximab, and Abatacept).

[0216] In one embodiment, a compound of the invention is co-administered with another therapeutic agent for the treatment and/or prophylaxis of proliferative disorders; particular agents include but are not limited to: methotrexate, leukovorin, adriamycin, prenisone, bleomycin, cyclophosphamide, 5-fluorouracil, paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine, doxorubicin, tamoxifen, toremifene, megestrol acetate, anastrozole, goserelin, anti-HER2 monoclonal antibody (e.g. HerceptinTM), capecitabine, raloxifene hydrochloride, EGFR inhibitors (e.g. Iressa®, Tarceva™, Erbitux™), VEGF inhibitors (e.g. Avastin™), proteasome inhibitors (e.g., Velcade<sup>TM</sup>), Glivec® and hsp90 inhibitors (e.g., 17-AAG), Additionally, a compound of the invention may be administered in

[0217] In one embodiment, a compound of the invention is co-administered with another therapeutic agent for the treatment and/or prophylaxis of autoimmune diseases, particular agents include but are not limited to: glucocorticoids, cytostatic agents (e.g. purine analogs), alkylating agents, (e.g. nitrogen mustards (cyclophosphamide), nitrosoureas, platinum compounds, and others), antimetabolites (e.g. methotrexate, azathioprine and mercaptopurine), cytotoxic antibiotics (e.g. dactinomycin anthracyclines, mitomycin C, bleomycin, and mithramycin), antibodies (e.g. anti-CD20, anti-CD25 or anti-CD3 (OTK3) monoclonal antibodies, Atgam® and Thymoglobuline®), cyclosporin, tacrolimus, rapamycin (sirolimus), interferons (e.g., IFN-8), TNF binding proteins (e.g., infliximab (Remicade™), etanercept (Enbrel™), or adalimumab (Humira™)), mycophenolate, Fingolimod and Myriocin.

combination with other therapies including, but not limited to, radiotherapy or surgery. In a specific embodiment the proliferative disorder is selected from cancer.

[0218] In one embodiment, a compound of the invention is co-administered with another therapeutic agent for the treatment and/or prophylaxis of transplantation. rejection, particular agents include but are not limited to: calcineurin inhibitors (e.g. cyclosporin or tacrolimus (FK506)), mTOR inhibitors (e.g. sirolimus, everolimus), anti-proliferatives (e.g. azathioprine, mycophenolic acid), corticosteroids (e.g. prednisolone, hydrocortisone). Antibodies (e.g. monoclonal anti-IL-2Ra receptor antibodies, basiliximab, daclizumab), polyclonal anti-T-cell antibodies (e.g. anti-thymocyte globulin (ATG), anti-lymphocyte globulin (ALG)).


102191 In one embodiment, a compound of the invention is co-administered with another therapeutic agent for the treatment and/or prophylaxis of asthma and/or rhinitis and/or COPD, particular agents include but are not limited to: beta2-adrenoceptor agonists (e.g. salbutamol, levalbuterol, terbutaline and bitolterol), epinephrine (inhaled or tablets), anticholinergics (e.g. ipratropium bromide), glucocorticoids (oral or inhaled) Long-acting p2-agonists (e.g. salmeterol, formoterol, bambuterol, and sustained-release oral albuterol), combinations of inhaled steroids and long-acting bronchodilators (e.g., fluticasone/salmeterol,



# TIP 4 National phase information and Examination reports (WIPO CASE Dossier)



# TIP 4 National phase information and Examination reports (WIPO CASE Dossier)





#### PATENTSCOPE

PCT Biblio. Data | Description | Claims | National Phase | Notices | Drawings | Documents

Search International and National Patent Collections

WORLD INTELLECTUAL PROPERTY ORGANIZATION

Search Browse Translate Options News User: yo.takagi@wipt

Home > IP Services > PATENTSCOPE

#### 1. (WO2012065681) AUTOMATED LANDING OF UNMANNED AERIAL VEHICLES

Machine translation

International Application Status				
Date	Title	√iew	Download	
10.02.2017	International Application Status Report	HTML, PDF	PDF, XML	

	Published International Application				
Date	Title	√iew	Download		
24.05.2012	Initial Publication without ISR (A2 21/2012)	PDF (16p.)	PDF (16p.), ZIP(XML + TIFFs)		
26.07.2012	Later publication of international search report (A3 30/2012)	PDF (6p.)	PDF (6p.), ZIP(XML + TIFFs)		

Search and Examination-Related Documents				
	Date	Title	√iew	Download
	21.05.2013	(IB/373) International Preliminary Report on Patentability Chapter I	PDF (6p.)	PDF (6p.), ZIP(XML + TIFFs)
	18.05.2013	Written Opinion of the International Search Authority	PDF (5p.)	PDF (5p.), ZIP(XML + TIFFs)
	18.05.2013	English Translation of the Written Opinion of the International Search Authority	PDF (5p.)	PDF (5p.), ZIP(XML + TIFFs)
	04.06.2012	Translation of the ISR	PDF (2p.)	PDF (2p.), ZIP(XML + TIFFs)
	04.06.2012	International Search Report	PDF (3p.)	PDF (3p.), ZIP(XML + TIFFs)

	Related Documents on file at the International Bureau				
Date	Title	√iew	Download		
21.05.2013	(IB/326) Notification of Transmittal of Copies of International Preliminary Report on Patentability Chapter I	PDF (1p.)	PDF (1p.), ZIP(XML + TIFFs)		
21.05.2013	(IB/373) English Translation of International Preliminary Report on Patentability Chapter I	PDF (6p.)	PDF (6p.), ZIP(XML + TIFFs)		
12.03.2013	(IB/308) Notice Informing the Applicant of the Communication of the International Application to the Designated Offices	PDF (1p.)	PDF (1p.), ZIP(XML + TIFFs)		
17.07.2012	(IB/311) Notification Concerning Availability of Publication of the International Application	PDF (1p.)	PDF (1p.), ZIP(XML + TIFFs)		
12.06.2012	(IB/308) Notice Informing the Applicant of the Communication of the International Application to the Designated Offices	PDF (1p.)	PDF (1p.), ZIP(XML + TIFFs)		
24.05.2012	(IB/311) Notification Concerning Availability of Publication of the International Application	PDF (1p.)	PDF (1p.), ZIP(XML + TIFFs)		
24.05.2012	Application Body as Filed	PDF (15p.)	PDF (15p.), ZIP(XML + TIFFs)		
24.05.2012	(IB/301) Notification of receipt of record copy	PDF (1p.)	PDF (1p.), ZIP(XML + TIFFs)		

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

#### **TIP 5 WIPO Translate**



ORGANIZATION

# WIPO launched Neural Machine Translation (AI) for Asian Languages in October 2016



Search technology, terminology and brand-related information in our free global databases.

Download our other reference materials: publications, statistics, economic studies and more.

#### PATENTSCOPE

58,220,000 international and national patent documents

#### Global Brand Database

27,960,000 international and national records of trademarks, appella origin and emblems

#### ROMARIN

International marks recorded under the Madrid System

#### Global Design Database

1,700,000 industrial design registrations from the Hague System and participating national collections

#### WIPO Lex

14.100 records of national IP laws and treaties of some 200 countries

#### **WIPO Translate**

WIPO Translate is a ground-breaking "artificial intelligence"based translation tool for patent documents. It is available through the PATENTSCOPE database.

Press release Video

#### IP for development

Learn about our global cooperation and development activit assistance to IP offices. Consult information by country. Joi Center (TISC).

FINANCIAL TIMES

HOME WORLD US COMPANIES MARKETS OPINION WORK & CAREERS LIFE & ARTS

Artificial Intelligence and Robotics Added



Patent translator flies artificial intelligence flag for public sector

UN agency outpaces tech groups to develop machine adept with technical language




Robots at the Science London - entertaini



#### **WIPO Translate**

Competitive translation quality: BLEU scores:





# WIPO Translation beta version Chinese, Japanese - English

patentscope.wipo.int/translate/demoNmt.jsf English | Español | Français | 中文 | TRANSLATE Instant patent translation Home IP Services PATENTSCOPE Database Search WIPO translate [help/user guide] WIPO Translate Beta is a powerful instant translation tool, designed specifically to translate patent texts (currently Chinese to English only). Simply cut and paste text from any Chinese patent document into the box below, then click on "Translate" to get an English translation (examples of Chinese patent documents from PATENTSCOPE). This beta version WIPO Translate (Chinese to English) is currently being piloted. Please bear with us if you receive any errors related to capacity issues - we're currently working on increasing our server power. Text to be translated: Translate.


#### Related links

- WIPO Translate full version (all language pairs)
- WIPO Develops Cutting-Edge Translation Tool For Patent Documents



## **PATENTSCOPE:** learning resources

#### Video tutorials




#### **Webinars**

#### Register for upcoming webinars

- Overview of PATENTSCOPE (February 14 or 16, 2017)
- Complex queries in PATENTSCOPE (March 14 or 16, 2017)
- Result list and analysis tools in PATENTSCOPE (April 25 or 27, 2017)
- Cross-lingual Information Retrieval tool (CLIR) in details (May 9 or 11,2017)

# The Manual on Open Source Tools for Patent Analytics

- Aimed at exploring:
  - various free and open source tools which could be used for various patent analysis tasks by users in developing countries
  - Includes walkthrough for using selected software for various analytics tasks



https://wipo-analytics.github.io



# **WIPO Lex**

#### WIPO Lex – WIPO's IP Laws database

- IP Treaties
- National IP laws and regulations (more than 200 nations)
- Bibliographic data and a brief note of explanation
- Full text in the original language and in English
- Machine translation available
- More than 14,000 records

Home | Reference | WIPO Lex

#### **WIPO Lex**

WIPO Lex is a global database that provides free access to some national laws and treaties on intellectual property (IP) from some countries which are WIPO, WTO or UN Members. The WIPO Lex project was made possible through a common endeavor of the Member States and other relevant bodies who contribute continuously to enriching the collection. WIPO invites Member States and other IP stakeholders to expand and update the content by sending inputs and suggestions through WIPO-WTO common portal (IP authorities only) or through contact page (open to all).

Members' Profiles
Treaty Secretariat
WIPO-WTO Common Portal
Glossary
Partners
Brochure
How to Use

- About WIPO Lex
- Disclaimer and Copyright Notice
- Contact us

Subject Matter  Select a Topic  Search WIPO Lex	VIPO/WTO/UN Members	Chins (256) Chins (256) > Hong Kong, China (134) > Macao, China (32) Colombia (100) Comores (8)		
		Select a Topic		

Home > Reference > WIPO Lex

#### China

#### Decision Amending the Measures on Administrative Enforcement of Patents (issued by Order No. 71 of May 29, 2015, of the State Intellectual Property Office (SIPO))

Year of Version:	2015
Date of Entry into Force:	July 1, 2015
Date of Text (Issued):	May 29, 2015
Type of Text:	Implementing Rules/Regulations
Subject Matter:	Enforcement of IP and Related Laws, IP Regulatory Body, Patents (Inventions)
Available Texts:	
Chinese	国家知识产权局关于修改〈专利行政执法办法〉的决定 (经中华人民共和国国家知识产权局局务会于2015年5月29日审议通过,自2015年7月1日起施行) PDF HTM (Version with Automatic Translation Tool)
Chinese  Related Legislation:	于2015年5月29日审议通过,自2015年7月1日起施行) PDF HTM (Version with Automatic
	于2015年5月29日审议通过,自2015年7月1日起施行) PDF HTM (Version with Automatic Translation Tool)

**Shortcuts** 

China

WIPO Lex: Disclaimer and copyright notice



## WIPO's Response

- Legal Framework (IP treaties)
- Systems (PCT, Madrid, Hague, AMC)
- Global IP Infrastructure
  - Global IP Data Standardization (IPOs)
  - Global generation of digital IP data (IPOs)
  - Global Databases (IPOs and users)
- Global Platforms (IPOs and users)

# Use Global Platforms for Your IP Management

- Save cost of transmission of Priority Documents Digital Access System (DAS)
- Investigate competitors' patents
  WIPO CASE (feeding dossier info to PATENTSCOPE)
- Find partners for Green technology
  WIPO GREEN
- Find partners for new bio/medical products
  WIPO RE:SEARCH




# WIPO DAS (<u>Digital Access System</u> for transmitting priority documents)

# WIPO Digital Access System (DAS)

- DAS (Digital Access System) used by 14 IPOs
- A System that allows IPOs and applicants to securely exchange or submit a digital copy of priority documents to multiple IPOs

INTELLECTUAL PROPERTY

ORGANIZATION



Depositing priority documents via WIDO DAC

# WIPO CASE (Centralized Access to Search and Examination)

# **WIPO CASE Membership – Providing**

**Offices** 

Providing Offices	Notes		
Australia			
Brunei Darussalam	Final technical preparation		
Canada			
Chile	Final technical preparation		
China			
EPO			
Israel			
Japan			
Republic of Korea			
IB (PCT)	Providing office only, for PCT documentation.		
United Kingdom			
United States of America	Initially a providing office only.		

Over 30 million patent applications searchable in WIPO CASE (access given to participating IPOs only). However, dossier information of EPO, JPO, CIPO are made available at PATENTSCOPE. USPTO, SIPO (China), KIPO (Korea) and IP Australia dossier will be added soon.

# WIPO CASE Membership – Accessing Offices

Accessing-only Offices	Notes	Acc Office
Cambodia		Pap
<b>Eurasian Patent</b>		Guir
Organization		Phil
(EAPO)		Sinc
India		Sing
Indonesia		
Lao PDR		
Malaysia		Thai
Mongolia		
New Zealand	Indicated willingness to become a providing office.	Viet

Accessing-only Offices	Notes
Papua New Guinea Philippines	
Singapore	Indicated willingness to become a providing office.
Thailand	
Viet Nam	



## **Recent Usage**

Period: 2016, year to date (to September)

Total: 27,606 (based on Counts of Accessed Documents)

Top Offices:

	As	Prov	iding	Office
--	----	------	-------	--------


Office	Recent Usage		
	Count	Percentage of Total	
WO (PCT)	20896	76%	
AU	2108	8%	
GB	1466	5%	
CA	726	3%	
US	700	3%	
JP	663	2%	
CN	544	2%	
IL	430	2%	

As Accessing Office

Office	Recent Usage	
	Count	Percentage
		of Total
CN	8214	30%
JP	7868	29%
KR	4113	15%
EP	2213	8%
GB	1683	6%
PH	992	4%
AU	989	4%
CA	747	3%
ID	394	1%
NZ	120	0%

INTELLECTUAL PROPERTY ORGANIZATION

## **Public Access**



#### **Status**


- ■IP5 "Global Dossier" available to public in EP, JP and US
- Offices allowing public access: IP5, plus WO/PCT, AU, CA (more to confirm soon)
- Public access via Patentscope First 3 IPOs dossier available at the end of January 2017




### **Multi-stakeholder Platforms**

#### **WIPO GREEN**

#### WIPO Re:Search







### **WIPO Green**




https://www3.wipo.int/wipogreen

- The marketplace for sustainable technology: search functionality for technology providers and seekers
- Network of green technologies stakeholders
- Grouped in 9 technology areas



# WIPO Green example: Energy



#### WIPO Re:Search

- Initiative in the field of neglected deseases, tuberculosis and malaria
- Includes a database with information on availability of IP rights and other information
- Based on the principle of voluntary contribution

Provider	Aberystwith University African Institute of Biomedical Sciences and Sectionology (AtBST) Altrylam Cattech Center for Infectious Disease Research Center for World Health and Medicine (CWHM) Center of Excellence for Intellaria Diagnosia, University of Lagoo Drugs for Neglected Diseases Inflative (ONDI) Estat Estatis Institute GelaxoSmithidine (GSK) Infectious Disease Research Institute (IDRS) Infectious Disease Research Institute (IDRS) Infectious Disease Research Engineering and Biotechnology (ICGEB)	Kumasi Centre for Research in Tropical Medicine (KCRThir)     Liverpool School of Tropical Medicine (     https://doi.org/10.1006	Stantard University Swiss Tropical and Public Health Institute (MIT) Theodor Bitharz Research Institute – (TBRI Typanosumuses Research Centre at the Keoya Agriculture Research Institute (KARI) University of Barnoko, Mali University of Barnoko, Mali University of Budo, Cameroon
Disease:	Unknown or Others Buruli Ulcer Chagas disease (American Irypanosominsis) Cysticercosts Dengueldengue hemorithagic tever Dracuncularais (guinea-worm disease) Echanocoscosts Echanocoscosts Endemic treponematoses (Yaws) Foodborne trematode infections (Clonorchiasis, Fast	sciolasis.	Screening, Hits Data Hit-to-Lead Lead Series Pre-Clinical Candidate Dinical Candidate Dinical Candidate Marketed Product Enabling Technology (platform) Intelectual Property (patents) Formulation Disagnostic Tholi Vaccine Technology New Biological Enaty Other Data, Know-how, Services, Resources

WIPO
WORLD
INTELLECTUAL PROPERTY
ORGANIZATION

### Conclusion

- Global Databases
  - Brand DB
  - Design DB
  - PATENTSCOPE (5 Great TIPs)
  - WIPO Lex
- Global Platforms
  - DAS
  - WIPO CASE
  - WIPO GREEN
  - WIPO Re:Search



Thank you!

yo.takagi@wipo.int